PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

no persons are required to respond to a collection of information unless it contains a valid OMB control number. Under the Pape Complete if Known ubstitute for form 1449A/PTO Application Number 10/555,664 INFORMATION DISCLOSURE Filing Date November 4, 2005 STATEMENT BY APPLICANT Peter ASSAF et al First Named Inventor Art Unit 1614 (use as many sheets as necessary) **Examiner Name** Not Yet Assigned 30724 Attorney Docket Number 2 Sheet ı of **U.S. PATENT DOCUMENTS** Pages, Columns, Lines, Where Publication Date Name of Patentee or Examiner Cite Document Number MM-DD-YYYY Applicant of Cited Document Relevant Passages or Relevant Initials⁴ Figures Appear Number-Kind Code^{2 (if known)} 06-23-2005 Thatcher et al. US-2005/0137191 /S.L US-6,310,052 10-30-2001 Thatcher et al. 2 03-16-1999 Thatcher et al. US-5,883,122 3 09-15-1998 Thatcher et al. US-5,807,847 4 US-2002/0177622 Thatcher et al. 11-28-2002 5 Thatcher et al. 07-12-2005 US-6,916,835 6 12-29-1999 Thatcher et al. US-09/473,713 04-11-1995 Goodman et al. US-5,404,871 8 Goodman et al. US-5,542,410 06-6-1996 9 02-23-1999 Briggner et al. 10 US-5,874,063 Trofast 11-16-1999 11 US-5,983,956 Jakupovic et al. 04-24-2001 US-6,221,398 12 07-31-2001 Gao et al. 13 US-6,268,533 05-20-2003 Nadel et al. 14 US-6,566,324 Weinstein US-6,571,790 03-3-2003 15 US-6,637,430 10-28-2003 Voges et al 16

-	-	FOREIGN	PATENT DOC	UMENTS			
Examiner City No.		Foreign Patent Documents Country Code ³ : Number ⁴ : Kind Code ³ (if known)	1 40110411011 25410		of Patentee or of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
/S I /	18	PCT WO 01/49275	07-12-2001	Thatcher	et al.		1_
	19	PCT WO 03/086282	10-23-2003	Fang et al.			
1/	20	PCT WO 00/30614	02-2-2000	Bisrat et al.			\perp
V	21	PCT WO 99/55319	04-4-1999	Cooper			+
	 				**************************************		十
Examiner Signature		/Sun Jae Loewe/			Date Considered	12/28/2007	

11-25-2003

17

US-6,652,323

Yanda

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Recognition Appearance of the Paperwork Recognition of the Paperwor

Under the Paperw	votk Kedocija	no persons are required to respond to a collection of	Intormation unless it comains a valid	- Las : CV				
Substitute for form 1449A/PTO			Complete if Known Application Number 10/555,664					
T	NEADI	MATION DISCLOSURE	L					
			Filing Date	November 4, 2005				
\$	STATE	MENT BY APPLICANT	First Named Inventor	Peter ASSAF et al				
(use as many sheets as necessary)			Group Art Unit	Not Yet Assigned				
			Examiner Name					
Sheet	2	Of 2	Attorney Docket Number	30724				
		OTHER PRIOR ART – NON PATE						
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the				priate), title of the				
Initials No. litem (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.					Τ²			
10.1.7	22	Kumar et al. "Design, Synthesis, and Evaluation of α-Ketoheterocycles as Class C β-						
/S.L./		Lactamase Inhibitors", Bioorganic & Medicinal Chemistry, 9: 2035-2044, 2001.						
	23	Cavicchi et al. "Inhibition of Inducible Nitri	c Oxide Synthase in the H	luman Intestinal				
		Epithelial Cell Line, DLD-1, by the Inducer						
		Heme, and Nitric Oxide Donors", GUT, 47(
	24	Salas et al. "Nitric Oxide Supplementation Ameliorates Dextran Sulfate Sodium-						
	24	Induced Colitis in Mice", Laboratory Invest	002 Abstract					
		P.602, Col.1, Lines 3-19.	.gat.o, 02(3). 377 007, 2	002::::00:::00:;				
 }	25	Liede et al. "Structure Activity Polationship	s of 2 Aminothiazola De	rivatives as				
	23	Ueda et al. "Structure-Activity Relationships of 2-Aminothiazole Derivatives as Inducible Nitric Oxide Synthase Inhibitor", Chemical & Pharmaceutical Bulletin,						
ľ		inducible Nitric Oxide Synthase Inhibitor,	Line 2 Table					
		52(5): 634-637, 2004. Abstract, P.634, Col.:		, Line 2, Table				
	_	2, Expls. 5a, 5b, 7, P.636, Col.1, Lines 17-1	8, 25-39.	1 11 11 771				
	26	Münzel et al. "Evidence fpr Enhanced Vascular Superpxide Anion Production", The						
		Journal of Clinical Investigation, 95: 187-19	94, 1995.					
	27	Chung et al. Identification of the Subcellula	r Site for Nitroglycerin M	etabolism to				
		Nitric Oxide in Bovine Coronary Smoth Mu	iscle Cells", The Journal o	of Pharmacology				
		and Experimental Therapeutics, 253(2): 61	4-619, 1990.					
	28	McGuire et al. "Inhibition of NADPH-Cyto	chrome P450 Reductase a	nd Glyceryl				
ľ		Trinitrate Biotransformation by Diphenylen	eidononium Sulfate", Bio	chemical				
		Pharmacology, 56: 881-893, 1998.						
	29	Needleman et al. "Sulfhydryl Requirement	for Relaxation of Vascular	r Smooth				
	-	Muscle", The Journal of Pharmacology and	Experimental Therapeutic	cs. 187(2): 324-				
		331, 1973.		, , ,				
	30	Bueb et al. "Natural Polyamines Stimulate (G-Proteins" Biochemical	Journal, 282:				
	30	545-550, 1992.	3 I LOCUIII , Diocinciinoai					
		Loscalzo "N-Acetylcysteine Potentiates Inh	ibition of Platelet Aggrega	ation by				
	31			ation by				
		Nitroglycerin", Journal of Clinical Investiga	1101, /0: /03-/08, 1983.					
	32	Kurz et al. "Nitroglycerin Metabolism in Va						
\I/		Transferases and Relationship Between NO	and NO2-Formation", Bi	ocnemical				
Y		Journal, 292: 545-550, 1993.						
				i				

Signature	/Sun Jae Loewe/	Considered	12/28/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{**}CAMINER: Initial if reference considered, whether or not clatation to applicant.

**Applicant's unique citation designation number (optional). **Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14, this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.